<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Elisence – Phase 2: Medication Choice & Safety Engine</title>

    <style>
        body {
            margin: 0;
            font-family: Arial, Helvetica, sans-serif;
            background-color: #08172a;
            color: #e8f4fc;
            line-height: 1.6;
        }

        /* ======= HEADER ======= */
        header {
            background-color: #020617;
            padding: 1.8rem 0;
            border-bottom: 1px solid #1e293b;
            box-shadow: 0 6px 20px rgba(0, 0, 0, 0.6);
        }

        .header-inner {
            max-width: 1100px;
            margin: 0 auto;
            padding: 0 1.5rem;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .brand-block {
            display: flex;
            flex-direction: column;
        }

        .brand-title {
            font-size: 1.4rem;
            font-weight: 700;
            letter-spacing: 0.14rem;
        }

        .brand-sub {
            font-size: 0.85rem;
            color: #60a5fa;
        }

        nav.main-nav {
            display: flex;
            gap: 1.8rem;
        }

        nav.main-nav a {
            color: #e2e8f0;
            text-decoration: none;
            font-size: 0.92rem;
            letter-spacing: 0.05rem;
            text-transform: uppercase;
        }

        nav.main-nav a:hover {
            color: #38bdf8;
            text-decoration: underline;
        }

        nav.main-nav a.active {
            color: #38bdf8;
            font-weight: 600;
        }

        /* ======= MAIN CONTENT ======= */
        main {
            max-width: 1100px;
            margin: 2.4rem auto 3.2rem auto;
            padding: 0 1.5rem;
        }

        h1 {
            font-size: 1.9rem;
            margin-bottom: 0.6rem;
            color: #38bdf8;
        }

        .lead {
            font-size: 1rem;
            color: #cbd5f5;
            margin-bottom: 1.8rem;
        }

        .card {
            background: rgba(15, 23, 42, 0.95);
            border-radius: 18px;
            border: 1px solid #1e293b;
            box-shadow: 0 16px 50px rgba(0, 0, 0, 0.55);
            padding: 1.8rem 1.9rem;
            margin-bottom: 1.8rem;
        }

        .card h2 {
            margin-top: 0;
            margin-bottom: 0.8rem;
            font-size: 1.3rem;
            color: #7dd3fc;
        }

        .card p {
            margin: 0.4rem 0;
            font-size: 0.95rem;
            color: #e5f2ff;
        }

        .card ul {
            margin: 0.5rem 0 0.2rem 1.2rem;
            padding-left: 0.4rem;
        }

        .card li {
            margin-bottom: 0.4rem;
            font-size: 0.94rem;
        }

        .tagline {
            font-size: 0.95rem;
            color: #93c5fd;
            margin-bottom: 0.5rem;
        }

        .phase-label {
            font-size: 0.82rem;
            text-transform: uppercase;
            letter-spacing: 0.12rem;
            color: #94a3b8;
            margin-bottom: 0.4rem;
        }

        /* ======= RESPONSIVE ======= */
        @media (max-width: 900px) {
            .header-inner {
                flex-direction: column;
                align-items: flex-start;
                gap: 0.8rem;
            }

            nav.main-nav {
                flex-wrap: wrap;
                gap: 1.1rem;
            }

            main {
                padding: 0 1.2rem;
            }

            .card {
                padding: 1.5rem 1.4rem;
            }
        }
    </style>
</head>
<body>

<header>
    <div class="header-inner">
        <div class="brand-block">
            <span class="brand-title">ELISENCE</span>
            <span class="brand-sub">Global Digital Health & Humanity Platform</span>
        </div>

        <nav class="main-nav">
            <a href="index.html">Home</a>
            <a href="index.html#phases">Phases</a>
            <a href="about.html">About</a>
            <a href="index.html#contact">Contact</a>
            <a href="story.html">Story</a>
            <a href="videos.html">Videos</a>
        </nav>
    </div>
</header>

<main>
    <div class="phase-label">PHASE 2</div>
    <h1>Medication Choice & Safety Engine</h1>
    <p class="lead">
        Phase 2 is the medication choice brain of Elisence. It does not prescribe or diagnose. Instead,
        it organises and compares medication options — starting with GLP-1 therapies — in a safe,
        transparent way for users, clinicians, and, in future, ministries of health.
    </p>

    <section class="card">
        <h2>What Phase 2 Is</h2>
        <p class="tagline">
            From “Which drug is right for me?” to a clear, structured, safety-first view.
        </p>
        <p>
            Phase 2 is designed to answer one of the hardest questions in modern metabolic and chronic care:
            <strong>“which medication, at which time, for which person, under which conditions?”</strong>
        </p>
        <p>
            It focuses first on GLP-1 and related metabolic therapies and then extends to broader drug classes.
            The engine can:
        </p>
        <ul>
            <li>Compare different GLP-1 options (e.g. Ozempic, Wegovy, Mounjaro) from a safety and suitability angle</li>
            <li>Highlight key differences such as dosing rhythm, indication, common side effects, and escalation patterns</li>
            <li>Map high-level benefit–risk considerations (non-diagnostic, non-prescriptive)</li>
            <li>Prepare structured summaries that clinicians can use during real consultations</li>
        </ul>
    </section>

    <section class="card">
        <h2>How It Feels for Users</h2>
        <p>
            For individuals and families, Phase 2 is not a medical calculator.
            It is a <strong>clarity layer</strong> sitting on top of confusing drug names and claims.
        </p>
        <ul>
            <li>Plain-language explanations of what each medication is intended to do</li>
            <li>Simple comparisons (e.g. “weekly injection vs daily tablet”, “weight focus vs diabetes focus”)</li>
            <li>Safety prompts like “this is a conversation to have with your doctor if you have X or Y condition”</li>
            <li>Guidance delivered through <strong>Elisa</strong> in a calm, non-judgmental way</li>
        </ul>
        <p>
            Phase 2 never tells users which medication to take, never adjusts doses,
            and never replaces the doctor–patient decision.
        </p>
    </section>

    <section class="card">
        <h2>How It Works for Clinicians & Clinics</h2>
        <p>
            For clinicians, Phase 2 is a structured background engine that helps them:
        </p>
        <ul>
            <li>See a consolidated view of relevant medication options for a given profile (e.g. GLP-1, SGLT2, or others later)</li>
            <li>Review key compatibility and high-level caution markers (e.g. kidney disease, pregnancy, severe GI issues)</li>
            <li>Receive a concise, printable or shareable summary to support shared decision-making with the patient</li>
        </ul>
        <p>
            Over time, Phase 2 can connect to national formularies, hospital guidelines, and
            health-authority restrictions, while keeping the final choice firmly with clinicians.
        </p>
    </section>

    <section class="card">
        <h2>Safety, Limits & Governance</h2>
        <p>
            Phase 2 follows strict safety boundaries:
        </p>
        <ul>
            <li><strong>Non-diagnostic:</strong> never labels or confirms a disease.</li>
            <li><strong>Non-prescriptive:</strong> never chooses or adjusts a specific medication or dose.</li>
            <li><strong>Evidence-grounded:</strong> anchored in guideline-style data and transparent sources.</li>
            <li><strong>Zero-trust & audit-ready:</strong> every query and generated summary can be logged
                and later inspected through Phase 4 and Phase 8.</li>
        </ul>
        <p>
            The engine is built so that ministries, hospitals and regulators can see clearly how
            medication comparisons are generated, and where its boundaries are.
        </p>
    </section>

    <section class="card">
        <h2>Connection to the Wider Elisence Platform</h2>
        <p>
            Phase 2 does not work in isolation; it is designed to sit between real-world data and real-world decisions.
        </p>
        <ul>
            <li><strong>Phase 1:</strong> uses the weight, symptoms and GLP-1 history to add context to choices</li>
            <li><strong>Phase 3:</strong> converts chosen treatment plans into daily care, reminders and follow-up</li>
            <li><strong>Phase 7:</strong> respects women’s health specifics when considering safety and pathways</li>
            <li><strong>Phase 8:</strong> feeds anonymised patterns into risk engines and national dashboards</li>
            <li><strong>Phase 9:</strong> links diabetes-specific needs (HbA1c, hypoglycaemia risk, comorbidities)</li>
            <li><strong>Phase 16:</strong> aligns medication decisions with nutrition and lifestyle recommendations</li>
        </ul>
        <p>
            In short, Phase 2 is the <strong>medication choice layer</strong> inside Elisence –
            always supportive, always transparent, always within safe boundaries.
        </p>
    </section>
</main>

</body>
</html>
